Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » Sequencing » Study Verifies Potential for Monitoring Metastatic Breast Cancer with Cell-Free DNA in Blood

Study Verifies Potential for Monitoring Metastatic Breast Cancer with Cell-Free DNA in Blood

Mar 14, 2013
|
Andrea Anderson

NEW YORK (GenomeWeb News) – A proof-of-principle study appearing online last night in the New England Journal of Medicine suggests that circulating, cell-free DNA can serve as an effective blood-based marker for monitoring metastatic breast cancer in women undergoing treatment for the disease.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Same Old Error

The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.

Own Merits

NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.

Back to Neanderthals

Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.

PNAS Papers on Small Molecule From Soil Bacteria, Circulating Tumor Cell Chip, More

In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.

Jul
23
Featured Webinar

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

Sponsored by
Roche

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.